A study published in the Lancet shows that a combination treatment of selinexor and bortezomib once weekly, along with twice-weekly dexamethasone, is effective for patients with multiple myeloma who have been previously treated. The ongoing phase 3 Boston trial included 402 patients from 123 sites in 21 countries, randomly assigned to receive this combination treatment. The results suggest that this regimen is both effective and convenient for patients with multiple myeloma, offering a promising option for those who have not responded well to previous treatments.
Source link
Once-Weekly Regimen for R/R Multiple Myeloma Found Beneficial in Boston Trial
